Trial pipeline
What is actually
being tested.
Every intervention in a registered, currently-running human trial for hair loss, read from ClinicalTrials.gov and sorted by phase. Not the ones a press release says are coming — the ones with an accession number, a sponsor and an enrolment target.
Read from the registry (today) · recruiting · not yet recruiting · enrolling by invitation · active, not recruiting
- Trials listed
- 157
- Distinct interventions
- 251
- Registered phase 3 or 4
- 38
- With posted results
- 0
What this page is, exactly
- It is a mirror of a registry, not a news feed. Every value in the table is a field on a ClinicalTrials.gov record: the phase the sponsor registered, the status the sponsor last verified, the condition the sponsor entered. If this page and the registry disagree, the registry is right.
- Registration is not evidence. A Phase 3 entry means a sponsor has planned a Phase 3 trial and told a registry about it. It does not mean the drug works, that the trial will finish, or that it will ever be published. Trials are abandoned, and the abandoned ones do not announce it.
- Nothing here has been read or graded. No trial on this page has been assessed by anyone here, and the rows are not ranked by how promising anything is. They are ordered by phase and date, because those are the only two things this page can order by honestly.
- None of these trials has posted results. These are studies that are running or about to run. There is nothing to summarise yet, and this page will not summarise anything when there is — a result belongs beside the paper that reports it, in a guide, quoted.
- This is not a way to find a trial to join. It is a picture of a field. Eligibility, sites and contacts live on the registry record, and joining a trial is a conversation with a doctor. Nothing here is medical advice.
How a trial gets onto this page
A registry is authoritative about values and silent about selection. Every field on a record is checkable. Whether a record belongs on a hair-loss page is not a field at all — it is a query somebody wrote, and it is the only place a page like this can lie to you.
The mistake this page is built to avoid
The obvious key is the drug name, because drug names are what a reader recognises. It is wrong, and not hypothetically. NCT07318688 is a recruiting Phase 3 trial of HMI-115, sponsored by Hope Medicine, first posted in January 2026. HMI-115 is a prolactin-receptor antibody in development for androgenetic alopecia and for endometriosis — and NCT07318688 is the endometriosis one. Its registered condition is Endometriosis.
Every field a drug-keyed tracker would have printed about it is true. The row would still have been a lie, because a table of hair-loss trials makes the claim this is a hair-loss trial, and that claim is not in any field on the record.
So the key is the condition, twice over
- The search is
query.cond, neverquery.intr. 10 condition searches, printed in full at the bottom of this page, restricted to interventional studies with a status of recruiting, not yet recruiting, enrolling by invitation, active, not recruiting. - Then the study's own registered conditions have to pass.
query.condis a fuzzy search: searching it for hair loss also returns a study of a storybook explaining leukaemia to children, several actinic keratosis trials, and a regenerative-medicine study of inner-ear hearing loss. So a study is kept only when one of the condition strings the sponsor themselves registered matches a rule below — and that string is printed in the table, on the same row, as the reason the row is there.
Registered conditions that are kept
- alopeciaAlopecia, in any of its registered forms
- effluviumTelogen and anagen effluvium
- patternBaldness and pattern loss
- lossHair loss, shedding, thinning and breakage
- growthHair growth or density as the registered condition
- cicatricialThe primary cicatricial alopecias, by their own names
- hypotrichosisHypotrichosis and atrichia
- trichotillomaniaTrichotillomania and hair pulling
- abbrevRegistered as an abbreviation and nothing else
Checked first, and refused
- excessToo much hair, not too little
- sensoryCochlear hair cells
- assayHair as a sample medium, not as an outcome
The rule is strict on purpose, and it costs real trials. A scalp-cooling study registered only under Breast Cancer is about hair loss by any reasonable reading and is not on this page, because its sponsor did not register it as a hair-loss study. That exclusion is listed below rather than made quietly. The alternative — a person here deciding which off-condition trials are really about hair — is an editorial judgement no reader could check, which is the thing this rule exists to remove.
157 trials, most advanced first
112 sponsors · 77 industry-sponsored · 80 academic, government or investigator-led
- 9Phase 4
- 24Phase 3
- 5Phase 2/3
- 32Phase 2
- 12Phase 1/2
- 6Phase 1
- 9Early Phase 1
- 60Not applicable
| Intervention | Sponsor | Phase | Status | Registered condition | Registry |
|---|---|---|---|---|---|
|
Baylor College of Medicineother | Phase 4 | Not yet recruitingprimary completion 31 July 2026 (estimated) | Central Centrifugal Cicatricial Alopecia | NCT06998433on ClinicalTrials.gov |
Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA) |
Hayat Abad Medical Complex, Peshawarother gov | Phase 4 | Not yet recruitingprimary completion 15 August 2026 (estimated) | Alopecia AreataAlopecia Totalis (AT)Alopecia Universalis | NCT07406204on ClinicalTrials.gov |
Topical Methotrexate vs Minoxidil for Localized Alopecia Areata |
Jinnah Postgraduate Medical Centreother gov | Phase 4 | Not yet recruitingprimary completion 15 September 2026 (estimated) | Alopecia Areata | NCT07459933on ClinicalTrials.gov |
Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata |
Hayat Abad Medical Complex, Peshawarother gov | Phase 4 | Not yet recruitingprimary completion 1 October 2026 (estimated) | Alopecia Areata | NCT07453238on ClinicalTrials.gov |
|
University of Alabama at Birminghamother | Phase 4 | Active, not recruitingprimary completion 31 October 2026 (estimated) | Frontal Fibrosing Alopecia | NCT06240351on ClinicalTrials.gov |
|
Wake Forest University Health Sciencesother | Phase 4 | Recruitingprimary completion November 2026 (estimated) | Central Centrifugal Cicatricial Alopecia (CCCA) | NCT04207931on ClinicalTrials.gov |
Topical Simvastatin Versus Topical Steroid in Treatment of Alopecia Areata |
Assiut Universityother | Phase 4 | Not yet recruitingprimary completion 1 October 2027 (estimated) | Alopecia Areata | NCT06399783on ClinicalTrials.gov |
|
Erasmus Medical Centerother | Phase 4 | Recruitingprimary completion 1 November 2027 (estimated) | Alopecia Areata(AA)Alopecia Areata (AA)Alopecia Totalis/UniversalisAlopecia Universalis (AU)Alopecia Totalis (AT)Alopecia Areata (& Ophiasis) | NCT07381556on ClinicalTrials.gov |
|
Assiut Universityother | Phase 4 | Not yet recruitingprimary completion June 2028 (estimated) | Androgenetic AlopeciaAndrogenetic Alopecia (AGA) | NCT07518342on ClinicalTrials.gov |
Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss |
Applied Biology, Inc.industry | Phase 3 | Not yet recruitingprimary completion 17 October 2025 (estimated) | Androgenetic AlopeciaFemale Pattern BaldnessMale Pattern Baldness | NCT06501924on ClinicalTrials.gov |
|
Veradermics, Inc.industry | Phase 2/3 | Active, not recruitingprimary completion February 2026 (estimated) | Androgenetic AlopeciaAGAMale Pattern Baldness | NCT06724614on ClinicalTrials.gov |
Behavioral Treatment and Memantine in Body Focused Repetitive Behaviors |
University of Chicagoother | Phase 2/3 | Active, not recruitingprimary completion 16 April 2026 (actual) | Trichotillomania (Hair-Pulling Disorder)+ 1 other registered condition | NCT05796752on ClinicalTrials.gov |
Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia |
EMSindustry | Phase 3 | Recruitingprimary completion May 2026 (estimated) | Androgenetic Alopecia | NCT04594018on ClinicalTrials.gov |
|
Sheikh Zayed Federal Postgraduate Medical Instituteother | Phase 3 | Not yet recruitingprimary completion 1 May 2026 (estimated) | Androgenic Alopecia | NCT07273799on ClinicalTrials.gov |
Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia |
Applied Biology, Inc.industry | Phase 3 | Not yet recruitingprimary completion 11 September 2026 (estimated) | Chemotherapy Induced Alopecia+ 1 other registered condition | NCT06762548on ClinicalTrials.gov |
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia |
Industrial Farmacéutica Cantabria, S.A.industry | Phase 3 | Recruitingprimary completion October 2026 (estimated) | Androgenetic AlopeciaFemale Pattern Baldness | NCT05888922on ClinicalTrials.gov |
|
Veradermics, Inc.industry | Phase 3 | Active, not recruitingprimary completion December 2026 (estimated) | Androgenetic AlopeciaAGAMale Pattern Baldness | NCT06972264on ClinicalTrials.gov |
|
Pfizerindustry | Phase 3 | Active, not recruitingprimary completion 2 December 2026 (estimated) | Severe Alopecia Areata | NCT07029711on ClinicalTrials.gov |
Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss |
EMSindustry | Phase 3 | Not yet recruitingprimary completion January 2027 (estimated) | Female Pattern Baldness | NCT05824065on ClinicalTrials.gov |
Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth |
Applied Biology, Inc.industry | Phase 2/3 | Not yet recruitingprimary completion 19 March 2027 (estimated) | Telogen EffluviumFemale Pattern Hair LossFemale Pattern Hair Loss, Androgenic AlopeciaMale Pattern BaldnessAndrogenetic AlopeciaAndrogenetic Alopecia (AGA) | NCT06648850on ClinicalTrials.gov |
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata |
Sun Pharmaceutical Industries, Inc.industry | Phase 2/3 | Active, not recruitingprimary completion May 2027 (estimated) | Alopecia Areata | NCT03898479on ClinicalTrials.gov |
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) |
Veradermics, Inc.industry | Phase 3 | Active, not recruitingprimary completion June 2027 (estimated) | Androgenetic Alopecia (AGA)Androgenetic AlopeciaAGAFemale Androgenetic AlopeciaHair Loss | NCT07146022on ClinicalTrials.gov |
|
Chong Kun Dang Pharmaceuticalindustry | Phase 3 | Recruitingprimary completion 30 September 2027 (estimated) | Androgenetic Alopecia | NCT06916793on ClinicalTrials.gov |
|
Suzhou Kintor Pharmaceutical Inc,industry | Phase 2/3 | Not yet recruitingprimary completion 20 October 2027 (estimated) | Androgenetic Alopecia (AGA) | NCT06622824on ClinicalTrials.gov |
Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia |
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.industry | Phase 3 | Recruitingprimary completion December 2027 (estimated) | Androgenetic Alopecia | NCT07080931on ClinicalTrials.gov |
|
Triple Hair Incindustry | Phase 3 | Recruitingprimary completion December 2027 (estimated) | Androgenic Alopecia | NCT07435012on ClinicalTrials.gov |
|
Sun Pharma Japan Limitedindustry | Phase 3 | Recruitingprimary completion February 2028 (estimated) | Alopecia Areata | NCT07617597on ClinicalTrials.gov |
|
Eli Lilly and Companyindustry | Phase 3 | Recruitingprimary completion March 2028 (estimated) | Areata AlopeciaAlopeciaHypotrichosis+ 3 other registered conditions | NCT05723198on ClinicalTrials.gov |
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata |
Pfizerindustry | Phase 3 | Recruitingprimary completion 19 March 2028 (estimated) | Alopecia Areata | NCT06873945on ClinicalTrials.gov |
|
Pfizerindustry | Phase 3 | Recruitingprimary completion 26 April 2028 (estimated) | Alopecia Areata | NCT07733765on ClinicalTrials.gov |
|
Sun Pharmaceutical Industries, Inc.industry | Phase 3 | Recruitingprimary completion May 2028 (estimated) | Alopecia Areata | NCT07133308on ClinicalTrials.gov |
|
Eurofarma Laboratorios S.A.industry | Phase 3 | Not yet recruitingprimary completion July 2028 (estimated) | Female Pattern Hair LossFemale Pattern Hair Loss, Androgenic Alopecia | NCT07303322on ClinicalTrials.gov |
|
Eurofarma Laboratorios S.A.industry | Phase 3 | Not yet recruitingprimary completion 30 October 2028 (estimated) | Androgenetic AlopeciaAndrogenetic Alopecia (AGA) | NCT07529977on ClinicalTrials.gov |
|
AbbVieindustry | Phase 3 | Active, not recruitingprimary completion February 2029 (estimated) | Alopecia Areata | NCT07023302on ClinicalTrials.gov |
Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia |
Apsen Farmaceutica S.A.industry | Phase 3 | Not yet recruitingprimary completion 2 August 2029 (estimated) | Alopecia, Androgenetic | NCT07516561on ClinicalTrials.gov |
|
AbbVieindustry | Phase 3 | Recruitingprimary completion April 2030 (estimated) | Alopecia Areata | NCT06012240on ClinicalTrials.gov |
|
Pfizerindustry | Phase 3 | Recruitingprimary completion 26 June 2030 (estimated) | Severe Alopecia Areata | NCT07029828on ClinicalTrials.gov |
|
AbbVieindustry | Phase 3 | Recruitingprimary completion March 2032 (estimated) | Severe Alopecia Areata | NCT07772492on ClinicalTrials.gov |
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia |
Zel Skin and Laser Specialistsother | Phase 2 | Active, not recruitingprimary completion December 2024 (estimated) | Androgenetic Alopecia | NCT05456087on ClinicalTrials.gov |
|
National Institute of Blood and Marrow Transplant (NIBMT), Pakistanother gov | Phase 1/2 | Enrolling by invitationprimary completion 30 June 2025 (estimated) | Androgenetic AlopeciaAndrogenetic Alopecia (AGA) | NCT06764329on ClinicalTrials.gov |
Various Procedural Treatment Options for Androgenetic Alopecia |
Sheikh Zayed Medical Collegeother gov | Phase 2 | Not yet recruitingprimary completion July 2025 (estimated) | Androgenetic Alopecia | NCT06826001on ClinicalTrials.gov |
A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia. |
PDFE Pharma Innovations FZCOindustry | Phase 2 | Active, not recruitingprimary completion 14 August 2025 (estimated) | Alopecia, AndrogeneticBaldnessAndrogenetic Alopecia (AGA) | NCT07011485on ClinicalTrials.gov |
|
CERM INC.industry | Phase 1/2 | Recruitingprimary completion 1 November 2025 (estimated) | Hair Loss/BaldnessHair Thinning+ 6 other registered conditions | NCT06869252on ClinicalTrials.gov |
|
Nektar Therapeuticsindustry | Phase 2 | Active, not recruitingprimary completion 26 November 2025 (actual) | Alopecia Areata | NCT06340360on ClinicalTrials.gov |
|
National Taiwan University Hospitalother | Phase 2 | Not yet recruitingprimary completion 31 December 2025 (estimated) | Alopecia Areata | NCT06797310on ClinicalTrials.gov |
|
Ain Shams Universityother | Phase 1/2 | Not yet recruitingprimary completion 31 January 2026 (estimated) | Androgenetic Alopecia | NCT07112586on ClinicalTrials.gov |
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia |
Olix Pharmaceuticals, Inc.industry | Phase 1/2 | Recruitingprimary completion April 2026 (estimated) | Androgenetic Alopecia (AGA) | NCT07327359on ClinicalTrials.gov |
|
Q32 Bio Inc.industry | Phase 2 | Active, not recruitingprimary completion June 2026 (estimated) | Alopecia Areata | NCT06018428on ClinicalTrials.gov |
Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients |
PT. Prodia Stem Cell Indonesiaindustry | Phase 1/2 | Recruitingprimary completion 30 June 2026 (estimated) | Androgenetic Alopecia | NCT07429253on ClinicalTrials.gov |
Safety and Efficacy of VDPHL01 in Males and Females With AGA |
Veradermics, Inc.industry | Phase 2 | Active, not recruitingprimary completion August 2026 (estimated) | Androgenetic AlopeciaAGAMale Pattern Baldness | NCT06527365on ClinicalTrials.gov |
|
Nanfang Hospital, Southern Medical Universityother | Phase 2 | Recruitingprimary completion 31 August 2026 (estimated) | Androgenetic Alopecia (AGA) | NCT07335367on ClinicalTrials.gov |
Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia |
Moogene Medi Co., Ltdindustry | Phase 1/2 | Not yet recruitingprimary completion September 2026 (estimated) | Androgenetic Alopecia | NCT07490327on ClinicalTrials.gov |
|
Aldena Therapeuticsindustry | Phase 1/2 | Recruitingprimary completion October 2026 (estimated) | Alopecia Areata (AA) | NCT06826196on ClinicalTrials.gov |
|
Shenzhen People's Hospitalother | Phase 1/2 | Recruitingprimary completion 1 October 2026 (estimated) | Androgenic Alopecia | NCT07203599on ClinicalTrials.gov |
Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata |
NEXTGEN Bioscienceindustry | Phase 2 | Recruitingprimary completion 31 October 2026 (estimated) | Alopecia Areata | NCT06104839on ClinicalTrials.gov |
|
Zhang Hanother | Phase 2 | Recruitingprimary completion 10 November 2026 (estimated) | Androgenetic Alopecia (AGA) | NCT07693244on ClinicalTrials.gov |
Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia |
Shenzhen People's Hospitalother | Phase 2 | Recruitingprimary completion January 2027 (estimated) | Androgenetic Alopecia (AGA) | NCT07370519on ClinicalTrials.gov |
|
University of Chicagoother | Phase 2 | Not yet recruitingprimary completion February 2027 (estimated) | Trichotillomania (Hair-Pulling Disorder)TrichotillomaniaHair Pulling DisorderHair PullingHair-Pulling Disorder | NCT07282769on ClinicalTrials.gov |
Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia |
Applied Biology, Inc.industry | Phase 1/2 | Recruitingprimary completion 5 February 2027 (estimated) | Chemotherapy Induced Alopecia+ 1 other registered condition | NCT07397325on ClinicalTrials.gov |
Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults |
Yale Universityother | Phase 2 | Recruitingprimary completion 15 February 2027 (estimated) | Trichotillomania (Hair-Pulling Disorder) | NCT05207085on ClinicalTrials.gov |
|
Memorial Sloan Kettering Cancer Centerother | Phase 2 | Active, not recruitingprimary completion March 2027 (estimated) | Alopecia+ 1 other registered condition | NCT05778825on ClinicalTrials.gov |
|
Icahn School of Medicine at Mount Sinaiother | Phase 2 | Recruitingprimary completion 1 March 2027 (estimated) | Alopecia Areata+ 1 other registered condition | NCT07242638on ClinicalTrials.gov |
|
Icahn School of Medicine at Mount Sinaiother | Phase 2 | Recruitingprimary completion 5 April 2027 (estimated) | Central Centrifugal Cicatricial AlopeciaLichen Planopilaris | NCT07487948on ClinicalTrials.gov |
Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients |
CSPC Ouyi Pharmaceutical Co., Ltd.industry | Phase 2 | Not yet recruitingprimary completion 31 May 2027 (estimated) | Severe Alopecia Areata | NCT06562894on ClinicalTrials.gov |
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) |
Eli Lilly and Companyindustry | Phase 2 | Recruitingprimary completion June 2027 (estimated) | Alopecia Areata | NCT07533006on ClinicalTrials.gov |
|
Almirall, S.A.industry | Phase 2 | Recruitingprimary completion 23 June 2027 (estimated) | Alopecia Areata | NCT07311564on ClinicalTrials.gov |
Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA) |
Maryanne Makredes Sennaother | Phase 2 | Not yet recruitingprimary completion 10 October 2027 (estimated) | Frontal Fibrosing Alopecia | NCT07671157on ClinicalTrials.gov |
|
Emma Guttmanother | Phase 2 | Recruitingprimary completion 30 November 2027 (estimated) | Alopecia Areata | NCT05551793on ClinicalTrials.gov |
|
University of Chicagoother | Phase 2 | Not yet recruitingprimary completion December 2027 (estimated) | Trichotillomania (Hair-Pulling Disorder)+ 1 other registered condition | NCT05545891on ClinicalTrials.gov |
|
National Institute of Allergy and Infectious Diseases (NIAID)nih | Phase 2 | Recruitingprimary completion 1 December 2027 (estimated) | Alopecia Areata+ 1 other registered condition | NCT05398809on ClinicalTrials.gov |
|
Ohio State University Comprehensive Cancer Centerother | Phase 2 | Not yet recruitingprimary completion 31 December 2027 (estimated) | Chemotherapy-Induced Alopecia+ 4 other registered conditions | NCT07594678on ClinicalTrials.gov |
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata |
University of Minnesotaother | Phase 2 | Recruitingprimary completion 15 March 2028 (estimated) | Alopecia AreataAlopecia TotalisAlopecia Universalis | NCT06747611on ClinicalTrials.gov |
|
Restore Biologics Holdings, Inc. dba Xtresséindustry | Phase 1/2 | Not yet recruitingprimary completion 1 May 2028 (estimated) | Androgenetic Alopecia | NCT07482423on ClinicalTrials.gov |
|
Johns Hopkins Universityother | Phase 2 | Not yet recruitingprimary completion 25 May 2028 (estimated) | Central Centrifugal Cicatricial Alopecia (CCCA) | NCT07734870on ClinicalTrials.gov |
|
Dana-Farber Cancer Instituteother | Phase 2 | Recruitingprimary completion 1 June 2028 (estimated) | Chemotherapy-induced Alopecia+ 1 other registered condition | NCT04986579on ClinicalTrials.gov |
|
Epibiotechindustry | Phase 1/2 | Recruitingprimary completion 1 June 2028 (estimated) | Androgenetic Alopecia | NCT07618195on ClinicalTrials.gov |
|
Icahn School of Medicine at Mount Sinaiother | Phase 2 | Recruitingprimary completion 30 June 2028 (estimated) | Central Centrifugal Cicatricial AlopeciaFrontal Fibrosing Alopecia | NCT07508488on ClinicalTrials.gov |
|
Absci Pty Ltd.industry | Phase 1/2 | Recruitingprimary completion July 2028 (estimated) | Androgenetic Alopecia (AGA)+ 1 other registered condition | NCT07317544on ClinicalTrials.gov |
Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata |
Jiangsu vcare pharmaceutical technology co., LTDindustry | Phase 2 | Recruitingprimary completion 30 December 2028 (estimated) | Alopecia Areata | NCT07749716on ClinicalTrials.gov |
|
Icahn School of Medicine at Mount Sinaiother | Phase 2 | Recruitingprimary completion 31 March 2029 (estimated) | Alopecia Areata | NCT05866562on ClinicalTrials.gov |
Biologics in Folliculitis Decalvans : an Adaptative Trial Research |
Assistance Publique - Hôpitaux de Parisother | Phase 2 | Not yet recruitingprimary completion 1 November 2029 (estimated) | Folliculitis Decalvans (FD) | NCT07268534on ClinicalTrials.gov |
SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates |
Jules Bordet Instituteother | Phase 2 | Not yet recruitingprimary completion January 2030 (estimated) | Alopecia+ 2 other registered conditions | NCT07474558on ClinicalTrials.gov |
|
Otsuka Pharmaceutical Development & Commercialization, Inc.industry | Phase 1 | Active, not recruitingprimary completion 19 October 2026 (estimated) | Alopecia Areata (AA)+ 2 other registered conditions | NCT06799520on ClinicalTrials.gov |
|
Forte Biosciences, Inc.industry | Phase 1 | Recruitingprimary completion 10 March 2027 (estimated) | Alopecia Areata | NCT07205159on ClinicalTrials.gov |
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo |
Dren Bioindustry | Phase 1 | Active, not recruitingprimary completion May 2027 (estimated) | Alopecia Areata+ 1 other registered condition | NCT06602232on ClinicalTrials.gov |
|
HCW Biologicsindustry | Phase 1 | Recruitingprimary completion 16 July 2027 (estimated) | Alopecia Areata(AA) | NCT07049328on ClinicalTrials.gov |
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata |
Jiangsu vcare pharmaceutical technology co., LTDindustry | Phase 1 | Not yet recruitingprimary completion 30 December 2027 (estimated) | Alopecia Areata | NCT07762443on ClinicalTrials.gov |
|
Innovent Biologics (Suzhou) Co. Ltd.industry | Phase 1 | Recruitingprimary completion 31 December 2027 (estimated) | Severe Alopecia Areata+ 2 other registered conditions | NCT07554222on ClinicalTrials.gov |
Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia |
Northwestern Universityother | Early Phase 1 | Active, not recruitingprimary completion 24 January 2024 (actual) | Permanent Chemotherapy-induced Alopecia | NCT03831334on ClinicalTrials.gov |
|
Applied Biology, Inc.industry | Early Phase 1 | Recruitingprimary completion 19 October 2025 (estimated) | Chemotherapy Induced Alopecia+ 1 other registered condition | NCT07033845on ClinicalTrials.gov |
Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia |
Shanghai Zhongshan Hospitalother | Early Phase 1 | Recruitingprimary completion May 2026 (estimated) | Androgenetic Alopecia (AGA) | NCT07012486on ClinicalTrials.gov |
|
University of California, Davisother | Early Phase 1 | Active, not recruitingprimary completion 1 October 2026 (estimated) | Alopecia Areata | NCT07029204on ClinicalTrials.gov |
|
Applied Biology, Inc.industry | Early Phase 1 | Not yet recruitingprimary completion 19 October 2026 (estimated) | Chemotherapy Induced Alopecia+ 1 other registered condition | NCT07402330on ClinicalTrials.gov |
Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) |
Wake Forest University Health Sciencesother | Early Phase 1 | Active, not recruitingprimary completion November 2026 (estimated) | Central Centrifugal Cicatricial Alopecia | NCT05416333on ClinicalTrials.gov |
Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia |
Wake Forest University Health Sciencesother | Early Phase 1 | Not yet recruitingprimary completion July 2027 (estimated) | Androgenic Alopecia | NCT03474718on ClinicalTrials.gov |
|
Ohio State University Comprehensive Cancer Centerother | Early Phase 1 | Recruitingprimary completion 1 December 2027 (estimated) | Endocrine Therapy-Induced Alopecia+ 22 other registered conditions | NCT05417308on ClinicalTrials.gov |
|
Kimberly Meathrelindustry | Early Phase 1 | Not yet recruitingprimary completion 30 December 2027 (estimated) | Androgenetic Alopecia | NCT07739147on ClinicalTrials.gov |
|
Nanfang Hospital, Southern Medical Universityother | Not applicable | Active, not recruitingprimary completion 28 September 2024 (actual) | Androgenic Alopecia | NCT06697080on ClinicalTrials.gov |
Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia |
Sohag Universityother | Not applicable | Not yet recruitingprimary completion October 2024 (estimated) | Androgenic Alopecia | NCT06326359on ClinicalTrials.gov |
|
Ancient + Braveindustry | Not applicable | Recruitingprimary completion 25 November 2024 (estimated) | Hair Thinning+ 2 other registered conditions | NCT06603194on ClinicalTrials.gov |
Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Alopecia |
Jessa Hospitalother | Not applicable | Recruitingprimary completion January 2025 (estimated) | Chemotherapy-induced Alopecia | NCT05177289on ClinicalTrials.gov |
|
Industrial Farmacéutica Cantabria, S.A.industry | Not applicable | Recruitingprimary completion 1 June 2025 (estimated) | Androgenetic Alopecia | NCT06841458on ClinicalTrials.gov |
|
Luminate Medical, Inc.industry | Not applicable | Recruitingprimary completion July 2025 (estimated) | Chemotherapy Induced Alopecia | NCT06786078on ClinicalTrials.gov |
|
University of Salamancaother | Not applicable | Recruitingprimary completion 31 July 2025 (estimated) | Alopecia+ 7 other registered conditions | NCT06955702on ClinicalTrials.gov |
|
Universiti Tunku Abdul Rahmanother | Not applicable | Enrolling by invitationprimary completion August 2025 (estimated) | Androgenic AlopeciaAlopecia | NCT06292533on ClinicalTrials.gov |
Alleviation of Alopecia in Breast Cancer Patient Using Synbiotics Formula |
GenieBiome Limitedindustry | Not applicable | Recruitingprimary completion 18 August 2025 (estimated) | Hair Loss+ 1 other registered condition | NCT06560385on ClinicalTrials.gov |
|
Ablon Skin Institute Research Centerother | Not applicable | Active, not recruitingprimary completion September 2025 (estimated) | Thinning Hair | NCT06920758on ClinicalTrials.gov |
Impact of Low-Level Laser Therapy on Hair Regrowth Post PRP Treatment |
Superior Universityother | Not applicable | Active, not recruitingprimary completion 1 September 2025 (estimated) | Baldness | NCT07048626on ClinicalTrials.gov |
|
Universitätsklinikum Hamburg-Eppendorfother | Not applicable | Recruitingprimary completion 1 September 2025 (estimated) | Androgenetic Alopecia (AGA) | NCT07079657on ClinicalTrials.gov |
Comparison of Microneedling Along With Topical Vitamin D3 Versus Microneedling in Alopecia Areata |
Services Institute of Medical Sciences, Pakistanother gov | Not applicable | Active, not recruitingprimary completion 29 September 2025 (actual) | Alopecia Areata | NCT07243977on ClinicalTrials.gov |
|
Jinnah Postgraduate Medical Centreother gov | Not applicable | Not yet recruitingprimary completion 30 September 2025 (estimated) | Androgenetic Alopecia (AGA) | NCT07018349on ClinicalTrials.gov |
Effect of Minoxidil Solution Iontophoresis on Androgenic Alopecia |
Cairo Universityother | Not applicable | Not yet recruitingprimary completion 15 November 2025 (estimated) | Alopecia | NCT07056933on ClinicalTrials.gov |
|
Goldman, Butterwick, Fitzpatrick and Groffother | Not applicable | Not yet recruitingprimary completion 30 November 2025 (estimated) | Female Pattern Baldness | NCT06926023on ClinicalTrials.gov |
Technology Assisted Treatment of Trichotillomania: Open Trial |
HabitAware Inc.industry | Not applicable | Recruitingprimary completion 9 January 2026 (estimated) | Trichotillomania | NCT07224126on ClinicalTrials.gov |
|
The Center for Clinical and Cosmetic Researchother | Not applicable | Recruitingprimary completion 20 March 2026 (estimated) | Hair Thinning | NCT07041489on ClinicalTrials.gov |
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss |
Cooler Heads Care Inc.other gov | Not applicable | Recruitingprimary completion 31 March 2026 (estimated) | AlopeciaChemotherapy-induced AlopeciaHair Loss+ 1 other registered condition | NCT05484973on ClinicalTrials.gov |
Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning |
Recens Medical, Inc.industry | Not applicable | Active, not recruitingprimary completion May 2026 (estimated) | AlopeciaHair Thinning+ 1 other registered condition | NCT06999408on ClinicalTrials.gov |
|
Nutra Harmony LLCindustry | Not applicable | Active, not recruitingprimary completion 1 May 2026 (estimated) | Hair Thinning | NCT07520019on ClinicalTrials.gov |
Olistic_2025 for Hair Loss, Hair Growth, and Skin Improvement |
Bionos Biotech S.L.industry | Not applicable | Active, not recruitingprimary completion 4 May 2026 (estimated) | Hair LossFemale Pattern Hair Loss+ 1 other registered condition | NCT07300813on ClinicalTrials.gov |
6-Month Trial of Chinese Herbal Treatments for Hair Loss and Gray Hair |
Vita Green Pharmaceutical (H.K.) Ltd.industry | Not applicable | Recruitingprimary completion 30 June 2026 (estimated) | Alopecia+ 1 other registered condition | NCT06998680on ClinicalTrials.gov |
|
L'Orealindustry | Not applicable | Active, not recruitingprimary completion 31 July 2026 (estimated) | Hair Loss | NCT07556016on ClinicalTrials.gov |
|
Wake Forest University Health Sciencesother | Not applicable | Recruitingprimary completion August 2026 (estimated) | Central Centrifugal Cicatricial Alopecia | NCT04764331on ClinicalTrials.gov |
|
Olistic Research Labs S.L.industry | Not applicable | Recruitingprimary completion 31 August 2026 (estimated) | Telogen Effluvium | NCT07484061on ClinicalTrials.gov |
Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color |
Montefiore Medical Centerother | Not applicable | Recruitingprimary completion September 2026 (estimated) | Alopecia | NCT05213936on ClinicalTrials.gov |
|
Olistic Research Labs S.L.industry | Not applicable | Active, not recruitingprimary completion September 2026 (estimated) | Early Female Pattern Hair Loss (FPHL) | NCT07347145on ClinicalTrials.gov |
Prevention of Alopecia in Patients With Localised Breast Cancer |
Centre Francois Baclesseother | Not applicable | Active, not recruitingprimary completion 3 September 2026 (estimated) | Chemotherapy-induced Alopecia | NCT06011525on ClinicalTrials.gov |
|
Sohag Universityother | Not applicable | Not yet recruitingprimary completion 28 September 2026 (estimated) | Alopecia Areata | NCT07696585on ClinicalTrials.gov |
Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution for Androgenetic Alopecia |
Kasr El Aini Hospitalother | Not applicable | Recruitingprimary completion October 2026 (estimated) | Androgenic Alopecia | NCT07502976on ClinicalTrials.gov |
JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil |
Kasr El Aini Hospitalother | Not applicable | Recruitingprimary completion 1 October 2026 (estimated) | Androgenetic AlopeciaAndrogenic Alopecia | NCT07563036on ClinicalTrials.gov |
VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia |
Institute of Dermatology, Thailandother gov | Not applicable | Recruitingprimary completion 30 November 2026 (estimated) | Androgenetic Alopecia (AGA) | NCT07536100on ClinicalTrials.gov |
|
St. Jude Children's Research Hospitalother | Not applicable | Recruitingprimary completion December 2026 (estimated) | Alopecia | NCT04764357on ClinicalTrials.gov |
|
Restore Biologics Holdings, Inc. dba Xtresséindustry | Not applicable | Enrolling by invitationprimary completion December 2026 (estimated) | Hair Thinning | NCT07221773on ClinicalTrials.gov |
Study Evaluating Xtressé Gummy Supplement in Women With Self-Perceived Thinning Hair |
Restore Biologics Holdings, Inc. dba Xtresséindustry | Not applicable | Enrolling by invitationprimary completion December 2026 (estimated) | Hair Thinning | NCT07224555on ClinicalTrials.gov |
A Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth |
CynosureLutronicindustry | Not applicable | Active, not recruitingprimary completion December 2026 (estimated) | Androgenic Alopecia | NCT07588243on ClinicalTrials.gov |
|
Venus Conceptindustry | Not applicable | Recruitingprimary completion 15 December 2026 (estimated) | Androgenic Alopecia | NCT05938569on ClinicalTrials.gov |
|
Zagazig Universityother gov | Not applicable | Recruitingprimary completion 30 December 2026 (estimated) | Alopecia Areata | NCT06327581on ClinicalTrials.gov |
|
HabitAware Inc.industry | Not applicable | Recruitingprimary completion 31 December 2026 (estimated) | Trichotillomania | NCT05118633on ClinicalTrials.gov |
|
Szeged Universityother | Not applicable | Recruitingprimary completion 31 December 2026 (estimated) | Alopecia Areata+ 3 other registered conditions | NCT07250997on ClinicalTrials.gov |
|
Taipei Medical University WanFang Hospitalother | Not applicable | Active, not recruitingprimary completion 31 December 2026 (estimated) | Androgenic Alopecia | NCT07580521on ClinicalTrials.gov |
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals |
Massachusetts General Hospitalother | Not applicable | Active, not recruitingprimary completion January 2027 (estimated) | Trichotillomania+ 12 other registered conditions | NCT01075672on ClinicalTrials.gov |
|
Olistic Research Labs S.L.industry | Not applicable | Active, not recruitingprimary completion January 2027 (estimated) | Early Female Pattern Hair Loss (FPHL) | NCT07111299on ClinicalTrials.gov |
|
Charles Maysother | Not applicable | Recruitingprimary completion 1 January 2027 (estimated) | Alopecia | NCT07422376on ClinicalTrials.gov |
|
Polyclinic GrandMedother | Not applicable | Not yet recruitingprimary completion February 2027 (estimated) | Alopecia Areata+ 3 other registered conditions | NCT07705217on ClinicalTrials.gov |
Dietary Supplement for Telogen Effluvium Associated With GLP-1 Receptor Agonist Use |
Farmoquimica S.A.industry | Not applicable | Not yet recruitingprimary completion February 2027 (estimated) | Alopecia | NCT07783113on ClinicalTrials.gov |
|
Lumenis Be Ltd.industry | Not applicable | Recruitingprimary completion 21 February 2027 (estimated) | Hair Loss | NCT06885112on ClinicalTrials.gov |
Study to Evaluate Xtresse Serum in Individuals With Thinning Hair |
Restore Biologics Holdings, Inc. dba Xtresséindustry | Not applicable | Active, not recruitingprimary completion March 2027 (estimated) | Hair LossAlopeciaThinning Hair+ 1 other registered condition | NCT07228156on ClinicalTrials.gov |
Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia |
Restore Biologics Holdings, Inc. dba Xtresséindustry | Not applicable | Not yet recruitingprimary completion April 2027 (estimated) | Androgenic AlopeciaHair Loss/BaldnessHair Thinning | NCT07637071on ClinicalTrials.gov |
|
University of Miamiother | Not applicable | Recruitingprimary completion 26 April 2027 (estimated) | Frontal Fibrosing Alopecia | NCT07340671on ClinicalTrials.gov |
Comparison Between Platelet Rich Plasma and Nanofat as an Adjuvant Therapy in HairTransplantation |
Sohag Universityother | Not applicable | Not yet recruitingprimary completion June 2027 (estimated) | Androgenic Alopecia | NCT07287579on ClinicalTrials.gov |
|
George Washington Universityother | Not applicable | Active, not recruitingprimary completion September 2027 (estimated) | Chemotherapy Induced Alopecia+ 5 other registered conditions | NCT07201389on ClinicalTrials.gov |
Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site) |
Acorn Biolabs Inc.industry | Not applicable | Recruitingprimary completion 15 September 2027 (estimated) | Androgenic AlopeciaAlopeciaBaldness | NCT07107841on ClinicalTrials.gov |
|
Chang Gung Memorial Hospitalother | Not applicable | Not yet recruitingprimary completion 30 September 2027 (estimated) | Androgenetic Alopecia | NCT07248410on ClinicalTrials.gov |
Non-Ablative Laser to Treat Scarring Alopecia With Hair Follicle Gene Expression Analysis |
Montefiore Medical Centerother | Not applicable | Recruitingprimary completion December 2027 (estimated) | Scarring Alopecia | NCT06946550on ClinicalTrials.gov |
1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia |
Montefiore Medical Centerother | Not applicable | Recruitingprimary completion July 2028 (estimated) | Scarring AlopeciaAndrogenetic Alopecia | NCT05460611on ClinicalTrials.gov |
Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads) |
University of California, San Franciscoother | Not applicable | Active, not recruitingprimary completion 31 December 2029 (estimated) | Hair LossAlopeciaChemotherapy-induced Alopecia+ 2 other registered conditions | NCT06215469on ClinicalTrials.gov |
A Study on the Efficacy and Safety of Microneedling for Male Androgenetic Alopecia |
Cheng Zhouother | Not applicable | Not yet recruitingprimary completion 1 January 2030 (estimated) | Androgenetic Alopecia | NCT07758400on ClinicalTrials.gov |
|
Chinese University of Hong Kongother | Not applicable | Recruitingprimary completion 31 October 2030 (estimated) | Alopecia+ 26 other registered conditions | NCT04014413on ClinicalTrials.gov |
Phase, status, sponsor and condition are reproduced from each record and nothing has been added to them. "Not applicable" is the registry's own answer for a study of a device, a procedure or a behaviour, where the phase vocabulary does not apply — it is not a missing value.
What the condition rule turned away
10 studies came back from the searches above and did not pass, because nothing the sponsor registered as a condition names hair loss. They are listed so the rule can be argued with rather than believed. An exclusion nobody can see is indistinguishable from a bug.
-
Leukemia
NCT06360718 Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress.
-
Breast Cancer
NCT04630080 Alopecia Prevention Scalp Cooling in Chinese Breast Cancer Patients
-
Breast Cancer
NCT06818370 The Effect of Coconut Oil on Alopecia
-
Fat GraftingHair TransplantationLocalized Scleroderma
NCT06646146 Study on the Efficacy of Autologous Fat Grafting in Improving Hair Transplantation Outcomes for Patients With Localized Scleroderma-Related Alopecia
-
Breast CancerBreast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage III
NCT04180579 Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients
-
Obsessive-Compulsive DisorderTricholemmomaSkin-Picking
NCT05377125 Neural Mechanisms of Response Inhibition Training for OCRD
-
Mindfulness SkillsPsychosocial Education
NCT06777212 Mindfulness Intervention for Psychological and Family Dynamics in Children with Body-Focused Repetitive Behaviors
-
Cardiometabolic ConditionsHypertension (HTN)DyslipidemiaPre-diabetesType 2 Diabetes Mellitus (T2DM)Overweight (BMI > 25)Weight Loss Trial
NCT07387393 To Test the Effectiveness and Implementation Approach of a 3-month PILI Pasifika Program Lifestyle Program With Components of Social Determinants of Health Activities in Real-world Settings (Clinical and Non-clinical Settings) Across 3 Years
-
Sensorineural Hearing LossTinnitusAcoustic TraumaInner Ear InjuryNoise-Induced Hearing LossSudden Hearing LossVestibular Dysfunction
NCT07472023 Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss
-
Actinic Keratosis
NCT07144345 Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
What keying on the drug name would have cost
A rule that only ever admits is unfalsifiable, so the opposite search is run on every refresh — purely to be counted, never to add a row.
Every name below was searched with query.intr — the intervention-keyed search this page refuses to select on — against the same status filter. 806 distinct studies came back that are not in the table above, across 23 names. Each one is a study of a drug a hair-loss reader recognises, registered for something else. The per-name column below sums to 827, because a trial registered for two of these drugs is returned by both searches; the headline counts each study once.
| Intervention searched | Also developed for | Registered, running | Would have been wrongly listed | Example registered condition |
|---|---|---|---|---|
| HMI-115 | developed in parallel for endometriosis | 1 | 1 | NCT07318688 Endometriosis |
| minoxidil | an antihypertensive first | 29 | 3 | NCT07548918 Vitiligo - Macular Depigmentation |
| finasteride | a prostate drug by volume of literature | 11 | 8 | NCT05663892 Hiv, Transgenderism |
| dutasteride | likewise | 12 | 10 | NCT01653925 Prostatic Neoplasms, Low Grade Prostate Cancer |
| spironolactone | a diuretic and a heart-failure drug | 48 | 48 | NCT05501080 Primary Aldosteronism |
| baricitinib | approved for rheumatoid arthritis | 53 | 48 | NCT02714634 Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide |
| ritlecitinib | also trialled in vitiligo and Crohn disease | 11 | 7 | NCT06072183 Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo |
| deuruxolitinib | a JAK inhibitor with oncology siblings | 2 | 0 | none — every running study of it is already in the table |
| ruxolitinib | a myelofibrosis drug | 184 | 183 | NCT07464951 Acute Myeloid Leukemia (AML) |
| upadacitinib | approved across several immune diseases | 56 | 53 | NCT02714634 Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide |
| ivarmacitinib | trialled across several immune diseases | 15 | 15 | NCT07641010 Hodgkin Lymphoma |
| clascoterone | approved as an acne topical | 7 | 7 | NCT07673094 Acne Vulgaris |
| pyrilutamide | an androgen-receptor antagonist | 0 | 0 | no running study is registered under this name |
| latanoprost | a glaucoma drug | 14 | 13 | NCT07209410 Glaucoma |
| bimatoprost | a glaucoma drug sold for eyelashes | 10 | 10 | NCT06761313 Glaucoma, Quality of Life (QOL) |
| ketoconazole | an antifungal | 14 | 14 | NCT03142893 Sleep Restriction |
| verteporfin | a photosensitiser used in macular degeneration | 7 | 7 | NCT07488988 Surgical Scar |
| platelet-rich plasma | injected into knees, faces and tendons | 206 | 199 | NCT07657871 Femoro-acetabular Impingement (FAI) |
| microneedling | a cosmetic procedure for scars and wrinkles | 48 | 42 | NCT07359339 Gingival Pigmentation |
| exosome | a delivery platform, not a hair drug | 106 | 99 | NCT06955767 Colorectal Adenocarcinoma |
| dihydroartemisinin | an antimalarial | 28 | 27 | NCT07557927 Discoid Lupus Erythematosus |
| 2-deoxy-D-ribose | a sugar studied for wound healing | 2 | 1 | NCT06502691 Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma |
| Lactobacillus reuteri | a probiotic studied for everything | 33 | 32 | NCT07347743 Colic, Healthy Infants, Eczema Atopic Dermatitis |
HMI-115 is the honest one to look at: the count is small, and the study behind it is a Phase 3 trial of a drug that genuinely is in development for hair loss. That is the whole difficulty. Ruxolitinib and platelet-rich plasma contribute hundreds of obviously-unrelated studies; HMI-115 contributes one that would have looked exactly right.
The exact searches
Printed in full, because a listing you cannot reproduce is a listing you have to take on trust. Every search is additionally restricted to interventional studies with a status of recruiting, not yet recruiting, enrolling by invitation, active, not recruiting — completed and terminated trials are deliberately absent, because this page's claim is present tense.
Androgenetic alopecia 56 registered · 56 passed the condition rule
Pattern hair loss in both sexes — the condition most of this site is about.
query.cond=androgenetic alopeciaRun this search on ClinicalTrials.gov Guides: Androgenetic Alopecia: Complete Guide, New Hair Loss Treatments in Clinical Trials: Clascoterone, Pyrilutamide and What the Published Data Actually Show, Complete Guide to Finasteride for Hair Loss, Minoxidil 5% Complete Guide: How to Apply for Best Results
Female pattern hair loss 13 registered · 13 passed the condition rule
Registered separately often enough that the androgenetic search alone misses trials enrolling only women.
query.cond=female pattern hair lossRun this search on ClinicalTrials.gov Guides: Female Pattern Hair Loss: Treatment Options That Work, Women's Hair Loss: The Complete Guide, Spironolactone for Hair Loss in Women
Alopecia areata 152 registered · 147 passed the condition rule
The fastest-moving area in the field, and where the JAK-inhibitor programmes are.
query.cond=alopecia areataRun this search on ClinicalTrials.gov Guides: Alopecia Areata: Types, Treatment, and Outlook, JAK Inhibitors for Alopecia Areata: Baricitinib, Ritlecitinib and Deuruxolitinib, Trial by Trial
Telogen effluvium 3 registered · 3 passed the condition rule
Diffuse shedding — small, mostly investigator-initiated, and almost never in a pipeline story.
query.cond=telogen effluviumRun this search on ClinicalTrials.gov Guides: Telogen Effluvium: Causes and Recovery Timeline, Diffuse Thinning vs. Pattern Baldness: How to Tell the Difference (2026 Guide), Hair Loss After Pregnancy: Recovery Guide
Frontal fibrosing alopecia 4 registered · 4 passed the condition rule
A scarring alopecia with no approved treatment, where what is in trials is the whole story.
query.cond=frontal fibrosing alopeciaRun this search on ClinicalTrials.gov Guides: Frontal Fibrosing Alopecia: Complete Guide to Symptoms, Causes & Treatment (2026)
Scarring alopecias 9 registered · 9 passed the condition rule
Lichen planopilaris, CCCA, folliculitis decalvans and the rest — the diagnoses that do not grow back.
query.cond=cicatricial alopeciaRun this search on ClinicalTrials.gov Guides: Scarring Alopecia Types and Management: Complete Guide, Frontal Fibrosing Alopecia: Complete Guide to Symptoms, Causes & Treatment (2026)
Traction alopecia 0 registered · 0 passed the condition rule
Included even though it usually returns nothing, because an empty row is a finding about the field.
query.cond=traction alopeciaRun this search on ClinicalTrials.gov Guides: Traction Alopecia: Prevention and Treatment
Chemotherapy-induced alopecia 19 registered · 17 passed the condition rule
Scalp cooling and the anagen-effluvium literature. Registered under the cancer as often as under the alopecia.
query.cond=chemotherapy-induced alopeciaRun this search on ClinicalTrials.gov Guides: Chemotherapy Hair Loss: Which Drugs Cause It, What Scalp Cooling Achieves, and the Regrowth Timeline
Trichotillomania 9 registered · 7 passed the condition rule
Hair loss with a cause no drug in the other rows addresses.
query.cond=trichotillomaniaRun this search on ClinicalTrials.gov Guides: Trichotillomania (Hair-Pulling Disorder): How It Is Diagnosed, What Treatment Has Trial Evidence, and Whether the Hair Grows Back
Hair loss (unqualified) 158 registered · 150 passed the condition rule
The catch-all, and the noisiest: it is where the supplement studies and the scalp-cooling trials live. Everything it returns still has to pass the condition rule below.
query.cond=hair lossRun this search on ClinicalTrials.gov Guides: Diffuse Thinning vs. Pattern Baldness: How to Tell the Difference (2026 Guide), How to Tell If You're Going Bald: Early Signs & Self-Assessment Guide (2026)
Data from ClinicalTrials.gov, a service of the U.S. National Library of Medicine. The registry is the authority on these records; where this page and the registry disagree, the registry is right. This page is not affiliated with or endorsed by NLM or NIH, and no trial listed here has any relationship with this site.
The guides this sits beside
A guide is a snapshot and this is a feed; they answer different halves of the same question. The guides explain what a treatment is and what the published evidence for it shows. This page only tells you what is currently registered as being studied.
Androgenetic Alopecia: Complete GuideNew Hair Loss Treatments in Clinical Trials: Clascoterone, Pyrilutamide and What the Published Data Actually ShowComplete Guide to Finasteride for Hair LossMinoxidil 5% Complete Guide: How to Apply for Best ResultsFemale Pattern Hair Loss: Treatment Options That WorkWomen's Hair Loss: The Complete GuideSpironolactone for Hair Loss in WomenAlopecia Areata: Types, Treatment, and OutlookJAK Inhibitors for Alopecia Areata: Baricitinib, Ritlecitinib and Deuruxolitinib, Trial by TrialTelogen Effluvium: Causes and Recovery TimelineDiffuse Thinning vs. Pattern Baldness: How to Tell the Difference (2026 Guide)Hair Loss After Pregnancy: Recovery GuideFrontal Fibrosing Alopecia: Complete Guide to Symptoms, Causes & Treatment (2026)Scarring Alopecia Types and Management: Complete GuideTraction Alopecia: Prevention and TreatmentChemotherapy Hair Loss: Which Drugs Cause It, What Scalp Cooling Achieves, and the Regrowth TimelineTrichotillomania (Hair-Pulling Disorder): How It Is Diagnosed, What Treatment Has Trial Evidence, and Whether the Hair Grows BackHow to Tell If You're Going Bald: Early Signs & Self-Assessment Guide (2026)